Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics has successfully raised A$20.0 million through a strategic placement of shares to international and Australian investors, strengthening its financial position. This funding will support the continued development of ATH434, a treatment for Multiple System Atrophy, and enhance the company’s clinical and regulatory strategies, positioning it for potential strategic partnerships.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company is based in Melbourne, Australia, and San Francisco, USA, and has demonstrated promising results with its lead asset, ATH434, in treating Multiple System Atrophy (MSA), a rare Parkinsonian disorder.
YTD Price Performance: 30.0%
Average Trading Volume: 13,758,518
Technical Sentiment Signal: Sell
Current Market Cap: A$119.7M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.